Table 3 MR-PRESSO results of the MR analysis
Outcome | Exposure | Raw | Outlier corrected | Global p | outliers | Distortion p | ||
|---|---|---|---|---|---|---|---|---|
OR_CI | P | OR_CI | P | Â | Â | Â | ||
Arterial embolism and thrombosis of lower extremity artery | Circulating plasma alpha-Klotho levels | 1.1493 (0.8205–1.6099) | 0.4636 | NA (NA–NA) | NA | 0.075 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | Fibroblast growth factor 23 levels | 1.6766 (1.0314–2.7255) | 0.0756 | NA (NA–NA) | NA | 0.251 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | Granulocyte proportions | 0.441 (8e-04–232.0941) | 0.8009 | NA (NA–NA) | NA | 0.142 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | GrimAge | 1.1536 (0.8906–1.4943) | 0.3582 | NA (NA–NA) | NA | 0.354 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | HannumAge | 1.0563 (0.9306–1.1989) | 0.4215 | NA (NA–NA) | NA | 0.639 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | IEAA | 1.0144 (0.9427–1.0915) | 0.7059 | NA (NA–NA) | NA | 0.466 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | PAI1 | 1.0001 (0.9998–1.0004) | 0.5703 | NA (NA–NA) | NA | 0.334 | NA | NA |
Arterial embolism and thrombosis of lower extremity artery | PhenoAge | 1.028 (0.9004–1.1737) | 0.6912 | 1.0798 (0.9684–1.2041) | 0.2005 | 0.034 | 1 | 0.56 |
Arterial embolism and thrombosis of lower extremity artery | Telomere length | 1.1093 (0.7665–1.6054) | 0.5831 | NA (NA–NA) | NA | 0.022 | NA | NA |
DVT of lower extremities | Circulating plasma alpha-Klotho levels | 1.2193 (0.8978–1.6558) | 0.2731 | 0.9674 (0.8727–1.0724) | 0.6422 |  < 0.001 | 3 |  < 0.001 |
DVT of lower extremities | Fibroblast growth factor 23 levels | 1.838 (0.6461–5.2292) | 0.2914 | 1.1056 (0.9653–1.2663) | 0.2429 |  < 0.001 | 4 |  < 0.001 |
DVT of lower extremities | Granulocyte proportions | 0.8852 (0.0887–8.8367) | 0.9185 | NA (NA–NA) | NA | 0.259 | NA | NA |
DVT of lower extremities | GrimAge | 1.0336 (0.9102–1.1737) | 0.6458 | NA (NA–NA) | NA | 0.226 | NA | NA |
DVT of lower extremities | HannumAge | 0.9857 (0.957–1.0152) | 0.3661 | NA (NA–NA) | NA | 0.975 | NA | NA |
DVT of lower extremities | IEAA | 0.963 (0.9386–0.988) | 0.0084 | NA (NA–NA) | NA | 0.829 | NA | NA |
DVT of lower extremities | PAI1 | 1 (0.9999–1) | 0.4038 | NA (NA–NA) | NA | 0.754 | NA | NA |
DVT of lower extremities | PhenoAge | 1.0322 (1.0002–1.0651) | 0.0765 | NA (NA–NA) | NA | 0.76 | NA | NA |
DVT of lower extremities | Telomere length | 0.9147 (0.7941–1.0537) | 0.219 | NA (NA–NA) | NA | 0.197 | NA | NA |
Other arterial embolism and thrombosis | Circulating plasma alpha-Klotho levels | 0.9483 (0.8036–1.119) | 0.5635 | NA (NA–NA) | NA | 0.733 | NA | NA |
Other arterial embolism and thrombosis | Fibroblast growth factor 23 levels | 1.661 (1.1137–2.4774) | 0.0417 | NA (NA–NA) | NA | 0.573 | NA | NA |
Other arterial embolism and thrombosis | Granulocyte proportions | 0.0132 (0–16.2968) | 0.2497 | NA (NA–NA) | NA | 0.105 | NA | NA |
Other arterial embolism and thrombosis | GrimAge | 0.9157 (0.8015–1.046) | 0.2852 | NA (NA–NA) | NA | 0.849 | NA | NA |
Other arterial embolism and thrombosis | HannumAge | 1.0611 (0.9181–1.2265) | 0.4451 | NA (NA–NA) | NA | 0.607 | NA | NA |
Other arterial embolism and thrombosis | IEAA | 0.9885 (0.9048–1.0801) | 0.8008 | NA (NA–NA) | NA | 0.279 | NA | NA |
Other arterial embolism and thrombosis | PAI1 | 1.0003 (1–1.0005) | 0.0871 | NA (NA–NA) | NA | 0.492 | NA | NA |
Other arterial embolism and thrombosis | PhenoAge | 1.0622 (0.9532–1.1837) | 0.3006 | NA (NA–NA) | NA | 0.358 | NA | NA |
Other arterial embolism and thrombosis | telomere length | 0.9246 (0.6187–1.3817) | 0.7025 | NA (NA–NA) | NA | 0.053 | NA | NA |
Phlebitis and thrombophlebitis | Circulating plasma alpha-Klotho levels | 1.1942 (0.9454–1.5084) | 0.2108 | 1.0406 (0.8516–1.2715) | 0.7639 | 0.002 | 3 | 1 |
Phlebitis and thrombophlebitis | Fibroblast growth factor 23 levels | 1.6514 (0.6913–3.945) | 0.2961 | 1.0933 (0.9438–1.2664) | 0.3001 |  < 0.001 | 3 |  < 0.001 |
Phlebitis and thrombophlebitis | Granulocyte proportions | 0.3401 (0.0334–3.4668) | 0.3753 | NA (NA–NA) | NA | 0.196 | NA | NA |
Phlebitis and thrombophlebitis | GrimAge | 0.9427 (0.8385–1.0598) | 0.3958 | NA (NA–NA) | NA | 0.227 | NA | NA |
Phlebitis and thrombophlebitis | HannumAge | 1.0106 (0.9525–1.0721) | 0.7363 | NA (NA–NA) | NA | 0.356 | NA | NA |
Phlebitis and thrombophlebitis | IEAA | 1.0061 (0.9694–1.0441) | 0.7517 | NA (NA–NA) | NA | 0.007 | NA | NA |
Phlebitis and thrombophlebitis | PAI1 | 0.9999 (0.9998–1.0001) | 0.3776 | NA (NA–NA) | NA | 0.25 | NA | NA |
Phlebitis and thrombophlebitis | PhenoAge | 0.9955 (0.9651–1.027) | 0.7836 | NA (NA–NA) | NA | 0.689 | NA | NA |
Phlebitis and thrombophlebitis | Telomere length | 1.1098 (0.9665–1.2742) | 0.1421 | 1.1228 (0.982–1.2839) | 0.0927 | 0.033 | 1 | 0.895 |
Portal vein thrombosis | Circulating plasma alpha-Klotho levels | 0.8749 (0.6344–1.2067) | 0.4611 | NA (NA–NA) | NA | 0.39 | NA | NA |
Portal vein thrombosis | Fibroblast growth factor 23 levels | 0.9412 (0.5018–1.7654) | 0.8557 | NA (NA–NA) | NA | 0.542 | NA | NA |
Portal vein thrombosis | Granulocyte proportions | 0.3368 (0–44,735.1727) | 0.8586 | NA (NA–NA) | NA | 0.016 | NA | NA |
Portal vein thrombosis | GrimAge | 0.9253 (0.5139–1.6661) | 0.8125 | NA (NA–NA) | NA | 0.132 | NA | NA |
Portal vein thrombosis | HannumAge | 1.1249 (0.9476–1.3354) | 0.2154 | NA (NA–NA) | NA | 0.86 | NA | NA |
Portal vein thrombosis | IEAA | 1.0204 (0.905–1.1505) | 0.7442 | NA (NA–NA) | NA | 0.46 | NA | NA |
Portal vein thrombosis | PAI1 | 1.0002 (0.9998–1.0006) | 0.3855 | NA (NA–NA) | NA | 0.435 | NA | NA |
Portal vein thrombosis | PhenoAge | 0.9804 (0.8018–1.1987) | 0.8509 | NA (NA–NA) | NA | 0.098 | NA | NA |
Portal vein thrombosis | Telomere length | 1.2326 (0.7546–2.0134) | 0.4049 | NA (NA–NA) | NA | 0.932 | NA | NA |
Pulmonary embolism | Circulating plasma alpha-Klotho levels | 1.1426 (0.9671–1.35) | 0.1923 | 1.0012 (0.9636–1.0403) | 0.9559 | 0.014 | 2 |  < 0.001 |
Pulmonary embolism | Fibroblast growth factor 23 levels | 1.6756 (0.873–3.2162) | 0.1647 | 1.2381 (1.1013–1.392) | 0.016 |  < 0.001 | 2 |  < 0.001 |
Pulmonary embolism | Granulocyte proportions | 0.588 (0.1459–2.3696) | 0.4654 | NA (NA–NA) | NA | 0.849 | NA | NA |
Pulmonary embolism | GrimAge | 0.9538 (0.9163–0.9928) | 0.1038 | NA (NA–NA) | NA | 0.86 | NA | NA |
Pulmonary embolism | HannumAge | 1.0257 (0.9818–1.0715) | 0.2883 | NA (NA–NA) | NA | 0.57 | NA | NA |
Pulmonary embolism | IEAA | 0.9759 (0.9488–1.0038) | 0.1037 | NA (NA–NA) | NA | 0.134 | NA | NA |
Pulmonary embolism | PAI1 | 1 (0.9999–1) | 0.1978 | NA (NA–NA) | NA | 0.644 | NA | NA |
Pulmonary embolism | PhenoAge | 1.0019 (0.9697–1.0352) | 0.9116 | NA (NA–NA) | NA | 0.399 | NA | NA |
Pulmonary embolism | Telomere length | 0.9247 (0.8079–1.0583) | 0.2577 | 0.9198 (0.8085–1.0463) | 0.2058 |  < 0.001 | 2 | 0.952 |
Venous thromboembolism | Circulating plasma alpha-Klotho levels | 1.1657 (0.9512–1.4286) | 0.2134 | 0.9661 (NaN–NaN) | NA |  < 0.001 | 4 |  < 0.001 |
Venous thromboembolism | Fibroblast growth factor 23 levels | 1.6847 (0.7696–3.6879) | 0.2332 | 1.2722 (1.2147–1.3325) | 0.0095 |  < 0.001 | 5 | 1 |
Venous thromboembolism | Granulocyte proportions | 0.5238 (0.1268–2.1643) | 0.3842 | NA (NA–NA) | NA | 0.144 | NA | NA |
Venous thromboembolism | GrimAge | 0.9769 (0.919–1.0385) | 0.5088 | NA (NA–NA) | NA | 0.397 | NA | NA |
Venous thromboembolism | HannumAge | 1.0091 (0.9915–1.0271) | 0.3417 | NA (NA–NA) | NA | 0.969 | NA | NA |
Venous thromboembolism | IEAA | 0.9865 (0.966–1.0074) | 0.2156 | NA (NA–NA) | NA | 0.063 | NA | NA |
Venous thromboembolism | PAI1 | 1 (1–1) | 0.0091 | NA (NA–NA) | NA | 0.994 | NA | NA |
Venous thromboembolism | PhenoAge | 1.0106 (0.9914–1.0302) | 0.3066 | NA (NA–NA) | NA | 0.67 | NA | NA |
Venous thromboembolism | Telomere length | 0.9443 (0.8494–1.0498) | 0.2909 | 0.9419 (0.8524–1.0408) | 0.2423 |  < 0.001 | 2 | 0.968 |